Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]
Discontinued
Reference number: GID-TA10583
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in early July 2024 when we will write to stakeholders about how they can get involved. The deadline for submissions is expected in approximately early September 2024.